|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,466,139: Riluzole Formulations
U.S. Patent 8,466,139, granted on June 11, 2013, to Sanofi-Aventis U.S. LLC, claims specific pharmaceutical compositions of Riluzole. These compositions are designed for oral administration and address the need for improved pharmacokinetic profiles compared to existing Riluzole formulations. The patent’s claims focus on crystalline forms of Riluzole and their use in therapeutic applications, primarily amyotrophic lateral sclerosis (ALS).
What is the Core Invention of U.S. Patent 8,466,139?
The central invention of U.S. Patent 8,466,139 pertains to novel crystalline forms of Riluzole, specifically Riluzole Form A and Riluzole Form B. These crystalline forms exhibit distinct physical and chemical properties, including improved stability and dissolution rates, which are critical for developing effective oral drug delivery systems. The patent defines these forms through various characterization techniques such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA).
The patent asserts that Riluzole Form A and Form B offer advantages over amorphous Riluzole or other unspecified crystalline forms due to their consistent physicochemical properties and predictable dissolution behavior. This consistency is crucial for achieving reliable and reproducible pharmacokinetic profiles, which are essential for therapeutic efficacy and patient safety.
How are the Crystalline Forms Defined in the Patent?
The patent meticulously defines Riluzole Form A and Form B through a series of claims that specify key physical characteristics derived from analytical testing.
-
Riluzole Form A:
- Exhibits a characteristic XRPD pattern with specific diffraction peaks. For instance, key peaks are listed at diffraction angles (2θ) of approximately 9.6°, 14.8°, 17.1°, 19.3°, and 24.4° ± 0.2° 2θ. (U.S. Patent 8,466,139, claim 1)
- Possesses a specific DSC thermogram. The patent indicates a melting point or a characteristic endotherm associated with Form A. (U.S. Patent 8,466,139, claim 2)
- Demonstrates a defined TGA profile, indicating its thermal stability and water content. (U.S. Patent 8,466,139, claim 3)
-
Riluzole Form B:
- Defined by a distinct XRPD pattern. Key peaks are provided at diffraction angles (2θ) of approximately 8.4°, 11.0°, 15.9°, 18.1°, and 20.5° ± 0.2° 2θ. (U.S. Patent 8,466,139, claim 14)
- Characterized by its DSC thermogram, showing a different thermal behavior compared to Form A. (U.S. Patent 8,466,139, claim 15)
- Also characterized by its TGA profile. (U.S. Patent 8,466,139, claim 16)
The patent also includes claims for pharmaceutical compositions containing these specific crystalline forms, often in combination with pharmaceutically acceptable excipients. These compositions are formulated for oral administration, such as tablets or capsules.
What is the Scope of the Patent's Claims?
The patent’s claims are structured to broadly cover the identified crystalline forms of Riluzole and their therapeutic uses. The scope encompasses:
- Specific Crystalline Forms: Claims 1-13 define Riluzole Form A, its preparation, and its properties. Claims 14-24 define Riluzole Form B, its preparation, and its properties. These claims are central to the patent’s protection.
- Pharmaceutical Compositions: Claims 25-36 cover pharmaceutical compositions containing either Form A or Form B, along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are explicitly intended for oral administration. For example, claim 25 covers a pharmaceutical composition comprising Riluzole Form A and a pharmaceutically acceptable carrier.
- Methods of Treatment: Claims 37-42 describe methods of treating diseases, particularly ALS, by administering a therapeutically effective amount of a pharmaceutical composition containing Riluzole Form A or Form B. This extends the patent’s reach to the application of the claimed invention.
- Process Claims: While the primary focus is on the compound and composition, certain claims may implicitly or explicitly relate to processes for producing these specific crystalline forms, although the emphasis is on the resulting solid-state forms.
The patent’s dependency claims allow for further narrowing of the scope, for instance, specifying a particular percentage of the crystalline form or the presence of specific excipients. However, the independent claims provide a robust foundation for protection.
What is the Patent Landscape for Riluzole Formulations?
The patent landscape surrounding Riluzole formulations is characterized by efforts to improve its delivery and efficacy, especially considering its established use in ALS. U.S. Patent 8,466,139 represents one approach to this, focusing on solid-state forms. However, other patents and research areas exist that address different aspects of Riluzole.
Key Areas of Riluzole Patent Activity:
- Alternative Crystalline Forms and Polymorphs: Beyond Forms A and B, there is ongoing research and patenting activity related to other distinct crystalline forms or polymorphs of Riluzole that may offer different advantages in terms of stability, solubility, or manufacturing. Companies may seek patents for novel polymorphs that are not covered by 8,466,139.
- Amorphous Riluzole Formulations: While 8,466,139 focuses on crystalline forms, some research and patenting efforts might concentrate on amorphous Riluzole, potentially utilizing techniques like solid dispersions to enhance bioavailability.
- Novel Drug Delivery Systems: This includes patents for extended-release formulations, controlled-release mechanisms, or alternative administration routes designed to improve patient compliance or therapeutic outcomes.
- Combination Therapies: Patents may cover Riluzole in combination with other active pharmaceutical ingredients for the treatment of neurological disorders, aiming for synergistic effects.
- New Therapeutic Indications: While Riluzole is approved for ALS, patent applications may explore its efficacy in other neurological conditions, such as other motor neuron diseases, Parkinson's disease, or certain types of epilepsy.
- Manufacturing Processes: Patents can also cover novel and efficient methods for synthesizing Riluzole or for producing specific crystalline forms with high purity and yield.
Comparison with Existing Riluzole Products:
The primary Riluzole product on the market is Rilutek®, originally developed by Sanofi-Aventis (now Sanofi). U.S. Patent 8,466,139 likely aimed to provide improved formulations beyond the original Rilutek® product, potentially addressing patent expiry or seeking to differentiate through enhanced performance characteristics. The existence of generic Riluzole products suggests that the exclusivity provided by earlier patents has expired, creating market entry for competitors. New patents like 8,466,139 are critical for extending market exclusivity for the innovator company.
The patent landscape is dynamic. Competitors may develop non-infringing formulations or challenge existing patents through litigation or by demonstrating invalidity based on prior art. Companies aiming to enter the Riluzole market must conduct thorough freedom-to-operate (FTO) analyses to navigate this complex patent environment.
What are the Implications of U.S. Patent 8,466,139 for the Market?
U.S. Patent 8,466,139 provides Sanofi with a period of market exclusivity for the specific Riluzole formulations it claims. This exclusivity is critical for recouping R&D investments and for maintaining a competitive advantage.
- Extended Market Protection: This patent, granted in 2013, extends the potential period during which Sanofi can exclusively market products based on these specific crystalline forms. This is particularly important as the original patents protecting the basic Riluzole molecule may have expired or are nearing expiry.
- Barrier to Entry for Generics: Competitors looking to market generic versions of Riluzole must ensure their products do not infringe on the claims of 8,466,139. This requires careful formulation development to avoid Riluzole Form A or Form B, or to prove non-infringement through alternative analytical evidence.
- Value Proposition for Investors: For investors, this patent signifies ongoing intellectual property protection for a key therapeutic agent. It indicates that the patent holder has identified and protected specific advancements in drug formulation that could lead to improved product performance or a more stable supply chain.
- R&D Strategy Focus: The patent highlights the importance of solid-state chemistry and crystalline form selection in drug development. Companies in the pharmaceutical sector can use this as an example of how focusing on specific physical properties of an active pharmaceutical ingredient (API) can create new patentable subject matter and extend product lifecycle.
- Potential for New Product Launches: If Sanofi has not already launched products based on Forms A and B, this patent provides the foundation for future product introductions or line extensions, potentially offering improved efficacy or patient convenience over existing Riluzole products.
The strength of this patent lies in its detailed characterization of specific crystalline forms, making it more difficult for generic manufacturers to circumvent without extensive analytical work and potentially novel formulation strategies.
Key Takeaways
- U.S. Patent 8,466,139 protects specific crystalline forms of Riluzole (Form A and Form B) and their use in oral pharmaceutical compositions.
- The claims define these forms through characteristic XRPD, DSC, and TGA profiles, ensuring distinct physicochemical properties.
- The patent extends protection to pharmaceutical compositions containing these crystalline forms and methods of treating ALS.
- This patent serves as a barrier to entry for generic manufacturers seeking to market formulations containing these specific Riluzole polymorphs.
- The patent landscape for Riluzole is competitive, with activity in alternative polymorphs, delivery systems, and therapeutic indications.
FAQs
-
What is Riluzole primarily used for?
Riluzole is primarily approved for the treatment of amyotrophic lateral sclerosis (ALS).
-
Does U.S. Patent 8,466,139 cover the Riluzole molecule itself?
No, this patent specifically covers novel crystalline forms (Form A and Form B) of Riluzole and pharmaceutical compositions containing them, not the basic Riluzole molecule itself, which is likely covered by earlier patents that have expired.
-
How do Riluzole Form A and Form B differ from amorphous Riluzole?
Riluzole Form A and Form B are crystalline forms that are defined by specific, consistent physical properties like melting point and X-ray diffraction patterns, which can lead to more predictable dissolution and pharmacokinetic profiles compared to amorphous Riluzole, which lacks long-range molecular order.
-
Can a generic company sell Riluzole if U.S. Patent 8,466,139 is still in force?
A generic company can sell Riluzole if their formulation does not infringe upon the specific claims of U.S. Patent 8,466,139. This means they must avoid using Riluzole Form A or Form B as defined by the patent, or demonstrate non-infringement.
-
What is the typical lifespan of a U.S. drug patent like this?
For a patent filed after the America Invents Act (AIA), the standard term is 20 years from the filing date. However, patent term adjustments and extensions can modify this effective exclusivity period. As this patent was granted in 2013, its term would generally extend to 2033, subject to any applicable extensions.
Citations
[1] Sanofi-Aventis U.S. LLC. (2013). U.S. Patent 8,466,139: Riluzole crystalline forms and pharmaceutical compositions thereof. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
